FIRST PRINCIPLE STRATEGIES ON BEHALF OF AMERICAN LABORATORIES PHARMA, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Manufacturing Domestic Supply Reforms
Registered Lobbyists (1)
JOSEPH KING ●NEW— former Deputy Chief of Staff Congressman Mark Meadows & former Sr. Advisor Congressman Greg Murphy, MD
IDs
Filing UUID:92554f63-ba8d-4819-bd9d-53775086bfc4
Registrant ID:401106174
Client ID:68890
2025-09-26
THE SMITH-FREE GROUP, LLC
SENIOR CARE PHARMACY COALITION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues pertaining to the long-term care pharmacy industry; Issues pertaining to the long-term care pharmacy industry
Registered Lobbyists (5)
JEFFREY BECKER ●NEW— Coalitions Coordinator, House Republican Conference; Staff Assistant, Rep. Liz CheneyJOHN CHRISTIE ●NEW— Chief of Staff, Rep. Alma Adams; Leg. Director, Rep. Alma Adams; Senior Leg. Assist., Rep. Alma Adams; Leg. Assist., Rep. Alma Adams; Leg. Correspondent/Leg. Aide, Rep. Norma TorresMICHAEL GAFFIN ●NEW— Leg. Director, Sen. Sherrod Brown; Leg. Director, Rep. Rob Andrews; Leg. Asst., Rep. Anna Eshoo; Jr. Leg. Assoc., House Ed and Labor Committee, Rep. George Miller; Staff Asst. Senate HELP Committee, Sen. Edward KennedyMIKE MULLEN ●NEW— Sr. Leg. Asst., Rep. Mike DoyleTREVOR KOLEGO ●NEW— Director of Member Services, Speaker John Boehner; Manager of Member Services, Leader John Boehner; Leg. Director, Rep. Jon Porter; Leg. Assist, Rep. Chris Cannon
IDs
Filing UUID:34e6d9bb-88c7-4850-97d1-da6eb5e5b06e
Registrant ID:35800
Client ID:68877
2025-09-24
DENTONS US LLP
PHARMACEUTICAL INDUSTRY LABOR MANAGEMENT ASSOCIATION (PILMA
$0
$0
Filing Details
Type: ld2 • Year: 2025 Q3
IDs
Filing UUID:e1167f8e-1f7f-4734-852a-e7d95063058d
Registrant ID:36105
Client ID:53148
2025-09-23
MICHAEL BEST STRATEGIES LLC
PUERTO RICO FISCAL AGENCY AND FINANCIAL ADVISORY AUTHORITY
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to agencies that affect the island of Puerto Rico, including the DOE, FEMA, DHS, and reshoring pharmaceutical supply chains; Issues related to agencies that affect the island of Puerto Rico, including the DOE, FEMA, DHS, and reshoring pharmaceutical supply chains; Issues related to agencies that affect the island of Puerto Rico, including the DOE, FEMA, DHS, and reshoring pharmaceutical supply chains
Registered Lobbyists (3)
ALEXANDER ANGELSON ●NEW— Special Assistant to the President, Office of Legislative Affairs, Executive Office of the PresidentBRITTAN SPECHT ●NEW— Counsel, Dep Chief of Staff, Hse Speaker; Policy Dir, Dep Policy Dir, Hse Min Leader.; Sr Policy Adv., Hse Maj. Leader; Policy Dr, RSC; Dep Chief of Staff Rep McClintock, Leg Asst & Financial Analyst, Rep. McClintockPRESTON HILL ●NEW— Sr Policy Advisor, House Speaker; Sr. Policy Advisor, Policy Advisor, House Minority Leader; Special Assistant, House Majority Leader
IDs
Filing UUID:51509a7a-be50-48e5-8c42-29dccff8ca94
Registrant ID:401103565
Client ID:68846
2025-09-22
CORNERSTONE GOVERNMENT AFFAIRS, INC.
NERVGEN PHARMA CORP.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Legislation related to neurotrauma drug approval and neurotrauma medical research.; Legislation related to neurotrauma drug approval and neurotrauma medical research.
Registered Lobbyists (4)
ASHLEY PALMER ●NEW— Dep Asst Sec, Cong. Affairs, HHS; Prof Staff Mem, Senate Approp Cmte;Sr Policy Advisor, Coalitions and Mem Services Svcs Aide, HouseBudget Cmte; Sr Leg Assistant, Leg Asst, House Mem Office (Boehner);Leg Asst, Staff Asst, House Mem Office (Putnam)CHRISTOPHER HODGSON ●NEW— Legislative Assistant (Scalise), Floor Assistant & Deputy Floor Director for House Majority Whip (Scalise), Deputy Director & Director of Legislative Affairs (Pence)JONATHAN MILLER ●NEWSUSAN SWEAT ●NEW— LC, LA & LD House Office (Wicker); LD Senate Member Office (Wicker)
IDs
Filing UUID:957cf25c-d0de-49e6-8ed6-c2cc4da35e99
Registrant ID:75557
Client ID:211044
2025-09-22
MEDSECUREAN.COM
LUPIN PHARMACEUTICALS
$14,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
Generic Industry Sustainability and tariifs broadly.; Tarrifs - generic medicine
Government Entities
Commerce, Dept of (DOC), Health & Human Services, Dept of (HHS), SENATE, State, Dept of (DOS), White House Office, U.S. Trade Representative (USTR)
Registered Lobbyists (1)
KATHLEEN JAEGER ●NEW
IDs
Filing UUID:fb336b40-a887-4e31-8559-9688a995b3cc
Registrant ID:401108536
Client ID:68809
2025-09-21
MEDSECUREAN.COM
INDIAN PHARMACEUTICAL ALLIANCE(FORMERLY INDIAN PHARMACEUTICAL ASSOCIATION)
$15,000
$0
Filing Details
Type: ld2 • Year: 2025 Q3
Specific Issues
The Indian Pharmaceutical Alliance (IPA) is dedicated to ensuring a level playing field in the U.S. pharmaceutical market and upholding the principles of the U.S. Hatch-Waxman Act to balance innovation with access. IPA members supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures. IPA actively supports targeted reforms to enhance the sustainability of the generic drug industry. Specifically, IPA advocates for substantial reforms of Pharmacy Benefit Managers (PBMs) and Group Purchasing Organizations (GPOs) to ensure transparent pricing and fair market practices that benefit consumers. Additionally, IPA champions efforts to close loopholes in the Hatch-Waxman Act that delay generic drug entry, facilitating timely access to affordable medications. These reforms are crucial for maintaining industry sustainability, reducing healthcare costs, and ensuring that effective, affordable treatment options remain accessible to all Americans. IPAs efforts underscore its pivotal role in promoting a healthy future for all Americans through enhanced access to affordable medicine and a robust, enduring pharmaceutical industry.; Indian Pharmaceutical Alliance is a trade association in India, representing key innovative and affordable medicine manufacturers. These manufacturers supply nearly 50% of Medicare Prescriptions, and of the top 10 U.S. therapeutic categories, the companies supply more than half of the prescriptions for 5 of the top 10 categories-ranging up to 60%. IPA members seek to explore U.S. - India supply chain resiliency partnership, and address affordable medicine sustainability reform measures.
Government Entities
Commerce, Dept of (DOC), Federal Trade Commission (FTC), Food & Drug Administration (FDA), Health & Human Services, Dept of (HHS), HOUSE OF REPRESENTATIVES, Office of Management & Budget (OMB), SENATE, State, Dept of (DOS), Treasury, Dept of, U.S. Trade Representative (USTR), White House Office, Natl Economic Council (NEC), Natl Security Council (NSC)
Registered Lobbyists (1)
KATHLEEN JAEGER ●NEW
IDs
Filing UUID:6f393ffc-2b2e-49a9-a9bb-79665bbc2e69
Registrant ID:401108536
Client ID:60141
2025-09-19
CORCORAN & ASSOCIATES, INC. DBA CORCORAN PARTNERS
ORCHARD THERAPEUTICS NORTH AMERICA
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues around health and pharmaceuticals; Issues around health and pharmaceuticals; Issues around health and pharmaceuticals
Registered Lobbyists (2)
MICHAEL CORCORAN ●NEWROBERT BLAIR ●NEW
IDs
Filing UUID:07a056c5-6a28-49b5-8a19-1079f55ddd2e
Registrant ID:401109009
Client ID:65681
2025-09-17
MARSHALL & POPP, LLC
CSL BEHRING
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.; Issues related to pharmaceutical manufacturing, drug pricing, trade and tariffs.
Registered Lobbyists (2)
HAZEN MARSHALL ●NEW— Policy Director-Senate Majority Leader Mitch McConnell; Staff Director, Senate Budget Committee-Senator Don Nickles; Deputy Chief of Staff/Economist, Office of Assistant Majority Leader-Senator Don Nickles; Legislative Assistant-Senator Don NicklesMONICA POPP ●NEW— Chief of Staff/Deputy Chief of Staff, Office of Senate Republican Whip John Cornyn; Professional Staff Member, U.S. House of Representatives-Energy & Commerce Committee; Legislative Assistant, Senator Jim DeMint
IDs
Filing UUID:5c1abbc2-8016-41f7-8fe2-3599654c3c35
Registrant ID:401105121
Client ID:68762
2025-09-15
GREENBERG TRAURIG, LLP
ONO PHARMACEUTICAL CO., LTD (FORMERLY ONO PHARMA USA)
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Legislative and regulator actions relating to drug approvals Issues relating to Pharmaceutical Manufacturing and Development; Legislative and regulator actions relating to drug approvals Issues relating to Pharmaceutical Manufacturing and Development
Registered Lobbyists (3)
CHARLES BASS ●NEW— U.S. Congressman (97 - 07) & (11 - 13)ROBERT MANGAS ●NEWRODNEY FRELINGHUYSEN ●NEW— U.S. Congressman (1995 - 2019)
IDs
Filing UUID:10610252-e479-4f37-9899-d406adf755f0
Registrant ID:16896
Client ID:52685
2025-09-09
BROWNSTEIN HYATT FARBER SCHRECK, LLP
CARDINAL HEALTH, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
General issues affecting the health care industry such as drug pricing, pharmaceutical drugs, medical devices, workforce shortages, and product shortages.
Registered Lobbyists (6)
AARON CUMMINGS ●NEW— Chief of Staff - Sen. Chuck Grassley; Chief Counsel, Constitution/Crime Counsel - Senate Judiciary Committee (Sen. Chuck Grassley)JAMES FLOOD ●NEW— Counsel - Senate Judiciary Committee (Sen. Schumer)SCOTT DOUGLAS ●NEWSTEPHEN HOLLAND ●NEW— Senior Health Counsel, Health Counsel - House Energy and Commerce Committee (Rep. Frank Pallone); Counsel, Legislative Assistant - Rep. Kurt SchraderTIM SHADYAC ●NEWTRACY TOLK ●NEW— Senior Policy Advisor, Senior Legislative Assistant - Rep. Jay Inslee; Senior Legislative Assistant, Legislative Assistant - Rep. Jim Davis
IDs
Filing UUID:2626788b-43cf-4857-85a7-fef0c9b67343
Registrant ID:7257
Client ID:68614
2025-09-08
TALLEY STRATEGIES LLC
TEVA PHARMACEUTICALS USA, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to pharmaceutical drug pricing; Issues related to pharmaceutical drug pricing
Registered Lobbyists (1)
AMBER TALLEY ●NEW— Senior Counsel/ Investigator, Senate Special Committee on Aging; Legislative Director, Chief of Staff, Rep. Jason Chaffetz; Counsel, House Oversight Committee
IDs
Filing UUID:b83f409b-3e87-4419-89ec-670d9b8c4388
Registrant ID:401109270
Client ID:68590
2025-09-05
EXECUTIVE STRATEGIES, LTD. CO.
SENTINEL API GROUP, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.; BIOSECURE Act implementation (H.R.8333) restricting Chinese pharmaceutical supply chains and supporting domestic API manufacturing. SBIR/STTR reauthorization (S.1573, H.R.3169) for pharmaceutical manufacturing eligibility. Strategic API Reserve funding under August 2025 Executive Order. FDA regulatory reforms including PreCheck Program and expedited facility approvals. Defense Production Act Title III pharmaceutical investments and Defense Manufacturing Community Support Program inclusion. HHS, ASPR, and BARDA appropriations for domestic manufacturing infrastructure.
Registered Lobbyists (1)
TYLER BEAVER ●NEW
IDs
Filing UUID:b1170da2-64e5-4144-8dd7-f46aa80764dd
Registrant ID:401109694
Client ID:68576
2025-09-04
CGCN GROUP, LLC
FRESENIUS KABI USA, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.; Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.; Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.; Sec. 232 investigation on pharmaceutical sector, tariffs, Buy America policies, Most Favored Nations Executive Order, reciprocal tariffs, essential medicines drug shortages related to trade agreements. U.S. manufacturing incentives. Buy America legislation, tariffs, tax incentives, regulatory barriers to generic and biosimilar launches, patent waivers. Section 232 investigation into pharmaceuticals and unfair trade practices.
Registered Lobbyists (2)
JILL HAMAKER ●NEWMARTHA MILLER ●NEW— Confidential Assistant, U.S. Department of Education, 2017-2019; Deputy Director of Scheduling, Sen. Ted Cruz (TX), 2019-2020; Scheduler, Rep. Warren Davidson (OH-08), 2020-2022.
IDs
Filing UUID:a58ab9a0-731e-4724-9a31-46d106f56967
Registrant ID:76992
Client ID:68558
2025-09-03
MEHLMAN CONSULTING, INC.
BETTER LIFE HEALTH, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues related to compounding pharmacies.
Registered Lobbyists (22)
ALEXANDER PERKINS ●NEW— Counsel, (Senator Ron Wyden), Trade Counsel (Ways and Means Subcommittee on Trade)ALYENE MLINAR ●NEW— Pol Adv (Maj Leader Scalise); Pol Adv (Min Whip Scalise); Pol Adv (House Oversight/Govt Reform Comm); Prof Staff Member (Ways and Means Subcom on Health/Brady), Pol Adv (Sen Rep Policy Comm/Barrasso); Leg Asst (Senator Ben Sasse)ANNIE WOLF ●NEW— Dep Floor Dir (Maj Leader Scalise); CoS (Chief Dep Min Whip Ferguson); Dep Floor Dir (Min Whip Scalise); Prof Staff (House Rules/Sessions); Floor Asst (Speakers Ryan & Boehner); Staff Asst (Speaker Boehner); Intern (Rep. Sullivan)BRUCE MEHLMAN ●NEW— Asst Sec of Commerce for Tech Pol; General Csl & Pol Dir (House Repub Conf)CAITLIN VAN SANT ●NEW— Sr Pol Adv, Leg Dir, Interim COS (Rep. Butterfield)DAVID THOMAS ●NEW— CoS (Rep. Lofgren); Dir of Congressional Relations (FTC); Dep Dir for Legis Affairs (Office of VP Gore); Staff Asst (Senator Metzenbaum)DEAN ROSEN ●NEW— Health Pol Dir (Senate Maj Ldr Frist); Staff Dir (Senate Pub. Health SC); Maj Health Pol Csl (House Ways/Means C, Health SC); Health Pol Coord & Csl (Senate Labor/HR C); Csl & Prof Staff (Senate Labor/HR C, Disab Pol SC); Case Wkr (Rep. Boschwitz)ELISE FINLEY PICKERING ●NEW— Exec Dir (House Repub Pol C); CoS (Rep. Shadegg); LA (Rep. Dannemeyer); LD (Rep. Bartlett)ERICA CHABOT ●NEW— Staff Dir (Sen Ag Comm); Dep CoS (Senate Consult); LD (Sen Pres Pro Temp Emeritus); Prof Staff (Sen Approp Comm); Leg Dir, Dep Press Sec, Press Asst, Asst to COS, Asst Schd, Leg Corres, Staff Asst, (Senator Patrick Leahy)HELEN TOLAR ●NEW— CoS (Senator Boozman); Staff Dir/Chief Csl - House VA C (Rep. Miller); Prof Staff/Csl - Senate VA C (Senator Craig); Csl/LD (Rep. Miller); LA (Rep. Miller); Scheduler (Rep. Miller); Law Clerk (House Trans/Infra C)JON ADAME ●NEW— CoS, LD, GC (Sen. Blackburn); Counsel (Rep. Blackburn); Policy Coordinator (House E&C); Intern (Sen. Domenici)JOSEPH BROWN ●NEW— Sr Prof Staff (EPW Comm Maj/Sen. Moore Capito); Prof Staff (EPW Comm Min/Ranking Mem Sen. Moore Capito); Leg Asst (Sen. Boozman); Maj Leg Asst (EPW Comm Maj/Sen. Jim Inhofe); Maj Research Asst (EPW Comm Maj/Sen. Jim Inhofe); Intern (Rep. Jim Renacci)LAUREN ARONSON ●NEW— Dir (Office of Legis, CMS); Prof Staff Mem, (House Ways/Means C); Pol Dir (White House); Pol Dir (HHS Office of Health Reform-detailed to White House); Pol Adv (Rep. Emanuel); Health LA (Rep. McCarthy)LISA GOLDMAN ●NEW— Sr Counsel, House Comm on Energy & Commerce; Chief Counsel, Sr Counsel (E&C Subcommittee on Consumer Protection & Commerce); Counsel House Comm on E&CMICHAEL ROBINSON ●NEW— Mem Svcs & Coalitions Dir (House Approp C); Pol Adv/Dep CoS (House Maj Ldr DeLay); LD (Rep. Rogers); Sr LA (Rep. Regula); Sr LA (Rep. Franks); LA (Rep. Rogers); Special Proj Asst (House Trans/Infra C); Staff Asst (Rep. Shuster)NAVEEN PARMAR ●NEW— Chief Counsel (Sen. Hickenlooper); General Counsel (House Comm on Sm Bus/Velazquez); Tax Counsel, (House Comm on Sm Bus/Velazquez); Economic Policy Counsel (Sen. Amy Klobuchar); Ways and Means Counsel (Rep. Lloyd Doggett)NICHOLE DISTEFANO ●NEW— LD, Sr Csl, Csl (Senator McCaskill); Assoc Admin, Dep Assoc Admin, Sr Adv (Office of Cong & Intergvt Relations, EPA)PAUL THORNELL ●NEW— Dep Dir of Legis. Affairs (Office of VP Gore); Assoc Dir-Senate Dem Steering Comm (Senator Daschle)ROSEMARY GUTIERREZ ●NEW— Dep COS, Leg Dir (Senator Cantwell); Prof staff, US Small Business Comm; Foreign Affairs Leg. Asst., (Senator Harkin)SAGE EASTMAN ●NEW— Strategy Dir, Dep Staff Dir (Maj), Sr Adv (House Ways/Means C); Comm Dir (Rep. Camp)STEPHEN COTE ●NEW— Staff Dir/Shrd Emp (House Fin Srvs/McHenry), Staff Dir, Dpt. Staff Dir, Sr. Pro Staff, Asst to L Diaz Balart (House Rules), Pol Coord Maj (House Homeland), Assoc Dir, Dpty Assoc Dir (OMB), CoS-DC, LD, LA (L Diaz Balart), LA, Staff Asst (Sen C. Mack)ZACHARY MALLOVE ●NEW— Sr Pol Adv, LA, Leg. Aide (Senator Murray); Leg. Aide, Joint Comm on Deficit Reduc.
IDs
Filing UUID:1404f8ef-0343-4a88-a37e-f6c238ca62fb
Registrant ID:284950
Client ID:68552
2025-08-28
CONTINENTAL STRATEGY, LLC
NRX PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Advocate for lifesaving treatments.
Registered Lobbyists (2)
CRAIG CARBONE ●NEW— Chief of Staff to Sen. Rick ScottTIMOTHY COSTA ●NEW— Chief of Staff to Dan Meuser
IDs
Filing UUID:84c4660d-f8dd-4de1-a1f3-0189b9e4a9b7
Registrant ID:401106285
Client ID:68511
2025-08-24
FIRST PRINCIPLES STRATEGIES, LLC
AMERICAN LABORATORIES PHARMA, LLC
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Manufacturing Domestic Supply Reforms
Registered Lobbyists (1)
JOSEPH MURRAY ●NEW— Republican Study Committee; Rep. Mark Meadows; & Senator Ron Johnson
IDs
Filing UUID:dce76316-99cd-4f1e-84c7-d1869397d158
Registrant ID:401104348
Client ID:68482
2025-08-14
MARBLE ARCH
ON DEMAND PHARMACEUTICALS
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Issues relating to securing the domestic pharmaceutical supply chain, ensuring reliable access to essential medications, and manufacturing of high-quality generic drugs in America.
Registered Lobbyists (1)
EMMA DOYLE ●NEW— Principal Deputy White House Chief of Staff; Deputy Chief of Staff for Policy to the First Lady; Chief of Staff, OMB; Acting Chief of Staff, CFPB; Legislative Assistant to Rep. Mick Mulvaney; Legislative Correspondent, Sen. Pat Toomey
IDs
Filing UUID:60e81f6f-eea3-4dd4-982b-9c36dc7943df
Registrant ID:401109131
Client ID:68395
2025-08-03
LMH STRATEGIC SOLUTIONS
REGENXBIO INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter
IDs
Filing UUID:37ecf87d-1698-44bb-bdcf-8eeb517d0e8c
Registrant ID:401108183
Client ID:68269
2025-07-28
THE MCMANUS GROUP
BRISTOL-MYERS SQUIBB
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
General issues related to pharmaceuticals
Registered Lobbyists (1)
JOHN MCMANUS ●NEW
IDs
Filing UUID:2faca55d-118f-4ac2-a48b-b8fd2322bfe4
Registrant ID:286096
Client ID:68220
2025-07-15
LMH STRATEGIC SOLUTIONS
ARDELYX, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter
IDs
Filing UUID:8e369302-0b49-4b42-8279-d61d7d65f1a6
Registrant ID:401108183
Client ID:67830
2025-07-15
LMH STRATEGIC SOLUTIONS
EXELIXIS, INC.
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter
IDs
Filing UUID:9ffdb0b8-9535-4c2a-b020-b1f05a1be647
Registrant ID:401108183
Client ID:67831
2025-07-15
LMH STRATEGIC SOLUTIONS
HARMONY BIOSCIENCES
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter
IDs
Filing UUID:730f8e1e-88d8-435e-9c2d-8fca9582bf9f
Registrant ID:401108183
Client ID:67832
2025-07-15
LMH STRATEGIC SOLUTIONS
INCYTE CORPORATION
$0
$0
Filing Details
Type: ld1 • Year: 2025 Q3
Specific Issues
Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.; Prescription drug payment reform. Pharmaceutical supply chain. General Medicare and Medicaid Issues.
Registered Lobbyists (1)
ALANNA TEMME ●NEW— Legislative Director, U.S. Representative Jon Porter